Skip to Content

Career Development Program

**2014-2015 CALL FOR RESEARCH PROPOSALS**

The Uterine SPORE will solicit proposals for 2014-2015 Career Development funding in late April 2014. Please download and review the Career Development RFA (pdf) for specific details.

 

Directors

George M. Stancel, Ph.D., David M. Gershenson, M.D., and Diane C. Bodurka, M.D.

SPORE guidelines mandate the identification and funding of career development research projects to attract new investigators or redirect established investigators to translational research in uterine cancer. Fellowship training for physicians in gynecologic oncology and gynecologic pathology usually emphasizes clinical care and clinical trials. Few graduates of such programs receive training that allows them to develop independent laboratory or translational research programs. Likewise, research specifically related to uterine cancer is not well represented in the basic sciences. Thus, there is a shortage of physician-scientists and basic scientists working in uterine cancer research.

Investigators awarded under this project convey new innovative ideas that can reduce the incidence and mortality of uterine cancers or improve the survival or quality of life of uterine cancer patients. The development of innovative translational researchers in uterine cancer is critically dependent on the availability of flexible funding for career development projects. The purpose of the Uterine SPORE Career Development Program (CDP) is to encourage and develop such translational research investigators. The CDP is designed to encourage investigators to develop translational research projects that will lead to clinically testable hypotheses with the potential to reduce incidence and mortality of uterine cancers or improve the survival and quality of life of uterine cancer patients. Both clinical and laboratory-based researchers are eligible for funding providing that they are proposing projects that are translational in nature. Funding is limited to a maximum of $50,000 per year per project, and two or more projects will be funded each year. Funding for additional projects may be provided from institutional commitment and the Uterine Cancer Research Program at MD Anderson. Awards are for 1 year, and awardees will be given the option to competitively renew for one additional year.

The objectives of the Career Development Program are as follows:

  1. Recruit and train new investigators to enable them to become highly skilled translational investigators in the field of uterine cancer.
  2. Redirect individuals who already have shown considerable scientific promise into uterine cancer research.
  3. Provide specific knowledge of research in uterine cancer that will enhance the ability of awardees to conduct innovative translational science that will directly impact on the understanding and treatment of this disease.
  4. Provide young investigators and those who are redirecting their research interests with an awareness of state of the art techniques that may be applied to human uterine cancer research, including microarray analysis, high throughput quantitative PCR, reverse phase protein arrays, laser microcapture dissection, proteomic analyses, informatics approaches, etc.
  5. Provide career enrichment activities such as grant writing skills, oral and poster presentation skills, and networking contacts to trainees.
  6. Provide a highly visible seminar program with outstanding speakers within the Texas Medical Center to attract undergraduate, graduate, and professional students, postdoctoral trainees, and faculty to the field of uterine cancer research and make them aware of major problems and opportunities existing in uterine cancer.
  7. Facilitate research collaborations with program faculty.

It is proposed that these objectives will be accomplished through strong individual mentorship and faculty relationships in which trainees are instructed in scientific methods, statistical analysis, biomedical communications, the principles of cancer biology, and strategies to become successful in the translational and uterine cancer research communities. Thus, the program will develop trainees who can readily identify basic science findings with translational potential and design protocols for clinical trials based on that translation.

Funding Information

  • Solicitations for proposals come out late spring/early summer each year.
  • Funding is for $50,000 total costs.
  • Funding is for 1 year beginning September 1 and ending August 31 each year.
  • A SPORE mentor must be contacted prior to submission of proposals/pre-applications.
  • A progress report will be due at the end of the funding period.
  • Competitive renewal for 1 additional year is allowed.

Please call or e-mail Kristi Mercer (713-792-6884, knmercer@mdanderson.org) for further information or to get on the e-mail list for solicitations. Also, you may check the SPORE website for updates on solicitations.

Career Development Awards

2003-2004

  • Jubilee Brown, M.D.
    UT MD Anderson Cancer Center
    Analysis of racial and ethnic differences in endometrial cancers
  • Limin Gong, Ph.D.
    UT MD Anderson Cancer Center
    Study of MR-1 in human endometrial cancer cells

2004-2005

  • Limin Gong, Ph.D. (Renewal)
    UT MD Anderson Cancer Center
    Study of MR-1 in human endometrial cancer cells
  • Brian Slomovitz, M.D.
    UT MD Anderson Cancer Center
    Clinical and translational evaluation of mTOR inhibition for the treatment of endometrial carcinoma

2005-2006

  • Jennifer Richer, Ph.D.
    University of Colorado Health Sciences Center
    ZEB1 in endometrial cancer
  • Salama A. Salama, Ph.D.
    UT Medical Branch
    Catechol estrogens and estrogen-metabolizing genes in endometrial cancer

2006-2007

  • Lei Deng, Ph.D.
    UT MD Anderson Cancer Center
    EIG121 as a molecular switch for endometrial carcinoma differentiation
  • Jae-Wook Jeong, Ph.D.
    Baylor College of Medicine
    The role of ERRFI1 in the tumorigenesis of endometrial cancer

2007-2008

  • Jae-Wook Jeong, Ph.D.
    Baylor College of Medicine
    The role of Mig-6 in the tumorigenesis of endometrial cancer
  • Jinping Li, M.D., Ph.D.
    Mayo Clinic/Mercer University
    Tumor promoting activity of human epididymis protein 4 (HE4) in endometrial cancer progression
  • Shannon N. Westin, M.D.
    UT MD Anderson Cancer Center
    Use of estrogen-regulated transcripts to predict response to intrauterine progesterone therapy in early endometrial disease

2008-2009

  • Bryan T. Hennessy, M.D.
    UT MD Anderson Cancer Center
    Targeting the PI3K Signaling Pathway in Endometrial Carcinoma

2010-2011

  • Adrienne S. McCampbell, Ph.D.
    UT MD Anderson Cancer Center
    The Role of AdipoR1 in Obesity Related Endometrial Proliferation and Cancer
  • Pamela T. Soliman, M.D.
    UT MD Anderson Cancer Center
    The Prevalence of Endometrial Abnormalities in Obese Women: An Evaluation of Molecular Markers

2011-2012

  • Shannon Hawkins, M.D., Ph.D.
    Baylor College of Medicine
    The Role of Pten and Dicer in Uterine Cancer Development
  • Ann H. Klopp, M.D., Ph.D.
    UT MD Anderson Cancer Center
    Visceral Adipose Stem Cells in the Endometrial Cancer Microenvironment

2012-2013

  • Ann H. Klopp, M.D., Ph.D. (Renewal)
    UT MD Anderson Cancer Center
    Visceral Adipose Stem Cells in the Endometrial Cancer Microenvironment
  • Han Liang, Ph.D.
    UT MD Anderson Cancer Center
    The Role of RNA Editing in Endometrial Tumorgenesis
  • Yuexin Liu, Ph.D.
    UT MD Anderson Cancer Center
    Molecular Classification of Endometrioid Carcinomas via Integrated Analysis

2013-2014

  • Han Liang, Ph.D. (Renewal)
    UT MD Anderson Cancer Center
    The Role of RNA Editing in Endometrial Tumorgenesis
  • Yuexin Liu, Ph.D.
    UT MD Anderson Cancer Center
    Identification of Molecular Biomarkers for Predicting High-Stage Endometrioid-type Endometrial Carcinomas
  • Ann H. Klopp, M.D., Ph.D. (Renewal)
    UT MD Anderson Cancer Center
    Therapeutic Opportunities Through Blockade of Malignant Prolactin in Endometrial Carcinoma

© 2014 The University of Texas MD Anderson Cancer Center